Maureen Deehan heads corporate development at Nordic Nanovector

Company
Nordic Nanovector ASA
Appointee name
Maureen Deehan
Country

Norway

Nordic Nanovector ASA has appointed Maureen Deehan as head of corporate development and strategy to work alongside its chief operating officer in overseeing the development of therapies for haematological cancers. Dr Deehan was most recently director of business development at the Swiss antibody company Novimmune SA. Prior to this, she was medical science liaison manager at Grünenthal UK.

Dr Deehan holds a PhD from the Faculty of Medicine at the University of Glasgow and a BSc in biochemistry and pharmacology from the University of Strathclyde, both in the UK.

Nordic Nanovector announced the appointment on 1 June 2018.

Copyright 2018 Evernow Publishing Ltd